DuPont De Nemours (DD) investor relations material

Executive summary

• Net sales reached $1.68 billion in Q1 2026, up 4% year-over-year, driven by healthcare and aerospace, with organic growth of 2% and a 2% currency benefit; construction softness and Middle East disruptions partially offset gains.

• Operating EBITDA rose 15% to $414 million, with margin expansion to 24.6%.

• Adjusted EPS increased 53% to $0.55 per share; GAAP income from continuing operations was $150 million, up 88%.

• Completed divestiture of the Aramids business for ~$1.2 billion in cash, a $300 million note, and $325 million in equity; announced a $275 million accelerated share repurchase.

• Announced new 2035 sustainability goals and continued innovation and operational excellence.

Financial highlights

• Net sales: $1.68 billion (+4% YoY); organic sales +2%, currency +2%.

• Operating EBITDA: $414 million (+15% YoY); margin 24.6% (+230 bps YoY).

• Adjusted EPS: $0.55 (+53% YoY); pro forma adjusted EPS +20%.

• Transaction-adjusted free cash flow: $147 million; conversion rate 65%.

• Cash from operations: $232 million; CapEx: $102 million.

Outlook and guidance

• Full year 2026 guidance raised: net sales $7.155–$7.22 billion, operating EBITDA $1.73–$1.76 billion, adjusted EPS $2.35–$2.40.

• Second quarter 2026 guidance: net sales ~$1.8 billion, operating EBITDA ~$430 million, adjusted EPS ~$0.59.

• Full year organic sales growth expected at ~4%, including ~1% from pricing actions.

• Segment expectations: Healthcare & Water Technologies to see mid-single digit organic growth; Diversified Industrials to see low-single digit growth.

• Guidance assumes current Middle East conflict conditions persist through year-end.